Trial Profile
ALIMTA [pemetrexed] plus gemcitabine as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer: a phase II clinical trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2006
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Aug 2006 Status change
- 19 Sep 2005 New trial record.